Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 14/20 | 0.86 |
| ▸ | PDE4B | Q07343 | 14/20 | 0.86 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.86 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.86 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.86 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3187308 | 0.97 | PDE4A (0.86) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL3179304 | 0.90 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL11462320 | 0.87 | PDE4A (0.74) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL24198811 | 0.83 | PDE4A (0.84) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL316279 | 0.83 | ADORA2B (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL1713323 | 0.82 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL1713301 | 0.81 | MEN1 (0.71) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL21381260 | 0.80 | ADORA2A (1.00) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL10955032 | 0.80 | ADORA2B (0.79) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL11466640 | 0.80 | PDE4A (0.65) | PDE4APDE4BPDE4CPDE4DADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20150080418-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2015-03-19 | — | — | US | disclosed |
| US-20130150383-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150383-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130150383-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2013-06-13 | — | — | US | disclosed |
| EP-1781657-B1 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-8394808-B2 | HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes | GLAXOSMITHKLINE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394808-B2 | HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes | GLAXOSMITHKLINE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394808-B2 | HM74 receptor agonists:xanthine derivatives, corresponding pharmaceutical compositions, treatment methods and processes | GLAXOSMITHKLINE LLC (US) | 2013-03-12 | — | — | US | disclosed |
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | HATLEY RICHARD JONATHAN DANIEL | 2009-08-20 | — | — | US | disclosed |
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | HATLEY RICHARD JONATHAN DANIEL | 2009-08-20 | — | — | US | disclosed |
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | HATLEY RICHARD JONATHAN DANIEL | 2009-08-20 | — | — | US | disclosed |
| EP-1805180-A1 | XANTHINE DERIVATIVES WITH HM74A RECEPTOR ACTIVITY | SmithKline Beecham Corporation (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070135456-A1 | Medicaments with hm74a receptor activity | GLAXOSMITHKLINE LLC | 2007-06-14 | — | — | US | disclosed |
| EP-1781657-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006045565-A1 | XANTHINE DERIVATIVES WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-04 | — | — | WO | disclosed |
| WO-2005077950-A2 | MEDICAMENTS WITH HM74A RECEPTOR ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135456-A1 | Medicaments with hm74a receptor activity | HCAR1, GPR84, HCAR3 | PDE4A 679/4885PDE4B 1199/4885PDE4C 1489/4885 |
| US-20150080418-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | PDE4A 408/4885PDE4B 592/4885PDE4C 850/4885 |
| US-20090209561-A1 | Xanthine Derivatives with HM74A Receptor Activity | XDH, HCAR1, GPR84 | PDE4A 417/4885PDE4B 787/4885PDE4C 1041/4885 |
| US-20130150383-A1 | NOVEL COMPOUNDS | HCAR1, XDH, GPR84 | PDE4A 408/4885PDE4B 592/4885PDE4C 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.